Avanthi Tayi Shah, MD
Pediatric Hematology-Oncology · Dallas
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Shah’s office at (214) 456-2382 to ask if they take your plan before you enroll.
California Medical Board record
Licence A124972 · Delinquent
Licence status: Delinquent · since 2013 · expires 2022-09-30 · University of Texas Southwestern Medical School at Dallas.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Texas P3978Physician License · since 2012 · expires 2026-11-30ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Medicaid work
$17,010 in 2024
Medicaid paid $17,010 for 224 billed services this clinician did in 2024, up to 22 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 224 | $17,010 |
| 2024 | 224 | 1 | 22 | $17,010 |
| 2023 | 148 | 1 | 20 | $10,216 |
| 2022 | 101 | 2 | 13 | $6,207 |
| 2021 | 391 | 5 | 23 | $24,164 |
| 2019 | 82 | 2 | 20 | $5,167 |
| 2018 | 76 | 1 | 13 | $4,522 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 148 | $10,216 |
2022
| Long return visit (40+ min) | 47 | $3,176 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 54 | $3,032 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 264 | $17,663 |
| OFF/OP EST MAY X REQ PHY/QHP | 49 | $3,091 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 29 | $1,635 |
| Long return visit (40+ min) | 36 | $1,466 |
| Blood count; blood smear, microscopic examination with manual differential WBC count | 13 | $310 |
2019
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 55 | $3,702 |
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 27 | $1,464 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 76 | $4,522 |
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 11 Part D prescriptions in 2016. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| JAZZ PHARMACEUTICALS INC. · Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed, ?Refractory Ewing Sarcoma · 2024 | Their institution | $117,529 |
| Eli Lilly and Company · A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared To Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy · 2025 | Their institution | $38,003 |
| Eli Lilly and Company · A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared To Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy · 2025 | This clinician | $17,893 |
| JAZZ PHARMACEUTICALS INC. · A Phase 1/2, Open-Label Study To Evaluate the Safety, Tolerability, Pharmacokinetics (Pk), Recommended Phase 2 Dose (Rp2d), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants With Previously Treated Solid Tumors Followed By Expansion To Assess Efficacy and Safety in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma. · 2024 | Their institution | $1,731 |
| JAZZ PHARMACEUTICALS INC. · A Phase 1/2, Open-Label Study To Evaluate the Safety, Tolerability, Pharmacokinetics (Pk), Recommended Phase 2 Dose (Rp2d), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants With Previously Treated Solid Tumors Followed By Expansion To Assess Efficacy and Safety in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma. · 2025 | Their institution | $1,258 |
| Blueprint Medicines Corporation · 2025 | Their institution | $250 |
Professional record
- NPI
- 1821230319
- Licence
- CA A124972, TX P3978California A124972: Delinquent · expires 2022-09-30Texas P3978: Active
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Pediatrics (208000000X)
- Mailing address
- Po Box 845347, Dallas, TX, 75284
- NPI first listed
- 2009-03-30
- NPI last updated
- 2020-12-14
- NPI record certified
- 2020-12-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1000 Welch Rd, Palo Alto, CA, 94304